- Home
- TKLF vs BIAF Comparison
TKLF vs BIAF Comparison
Compare TKLF & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- BIAF
- Stock Information
- Founded
- TKLF 2006
- BIAF 2014
- Country
- TKLF Japan
- BIAF United States
- Employees
- TKLF N/A
- BIAF N/A
- Industry
- TKLF Other Specialty Stores
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TKLF Consumer Discretionary
- BIAF Health Care
- Exchange
- TKLF Nasdaq
- BIAF Nasdaq
- Market Cap
- TKLF 14.2M
- BIAF 14.5M
- IPO Year
- TKLF 2022
- BIAF 2022
- Fundamental
- Price
- TKLF $3.30
- BIAF $0.68
- Analyst Decision
- TKLF
- BIAF Strong Buy
- Analyst Count
- TKLF 0
- BIAF 1
- Target Price
- TKLF N/A
- BIAF $6.00
- AVG Volume (30 Days)
- TKLF 48.7K
- BIAF 313.4K
- Earning Date
- TKLF 12-18-2024
- BIAF 11-14-2024
- Dividend Yield
- TKLF N/A
- BIAF N/A
- EPS Growth
- TKLF N/A
- BIAF N/A
- EPS
- TKLF 1.70
- BIAF N/A
- Revenue
- TKLF $219,520,631.00
- BIAF $9,367,785.00
- Revenue This Year
- TKLF N/A
- BIAF $285.51
- Revenue Next Year
- TKLF N/A
- BIAF $20.05
- P/E Ratio
- TKLF $1.94
- BIAF N/A
- Revenue Growth
- TKLF 32.02
- BIAF 2813.87
- 52 Week Low
- TKLF $2.00
- BIAF $0.66
- 52 Week High
- TKLF $8.53
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- TKLF 45.25
- BIAF 26.89
- Support Level
- TKLF $3.15
- BIAF $0.67
- Resistance Level
- TKLF $3.60
- BIAF $1.01
- Average True Range (ATR)
- TKLF 0.21
- BIAF 0.08
- MACD
- TKLF 0.00
- BIAF -0.01
- Stochastic Oscillator
- TKLF 22.09
- BIAF 4.29
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.